Cargando…
Daridorexant, a Recently Approved Dual Orexin Receptor Antagonists (DORA) in Treatment of Insomnia
Insomnia is one of the major challenges in medical science nowadays as it leads to great socio-economic burden by impairing daytime function as well as the development of exhaustion, depression, and memory disturbance in affected individuals. Several important classes of drugs have been tried, inclu...
Autores principales: | Sarathi Chakraborty, Dwaipayan, Choudhury, Shouvik, Lahiry, Sandeep |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Thieme Revinter Publicações Ltda.
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10325868/ https://www.ncbi.nlm.nih.gov/pubmed/37425970 http://dx.doi.org/10.1055/s-0043-1770805 |
Ejemplares similares
-
Lefamulin, a recently approved novel antibacterial agent to fight against community-acquired bacterial pneumonia
por: Choudhury, Shouvik, et al.
Publicado: (2021) -
Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia
por: Roch, Catherine, et al.
Publicado: (2021) -
A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia
por: Ziemichód, Wojciech, et al.
Publicado: (2022) -
Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment
por: Berger, Benjamin, et al.
Publicado: (2021) -
Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist
por: Krause, Andreas, et al.
Publicado: (2022)